SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Share-Based Compensation Expense

The following table displays share-based compensation expense recorded in the condensed consolidated statements of operations and comprehensive income (loss):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
	(dollars in millions)
Share-based compensation expense:
Loss and loss adjustment expenses	$	0.6	$	0.2	$	1.4	$	0.5
Sales and marketing	0.2		0.1		0.5		0.3
Other insurance expense	0.2		0.1		0.5		0.4
Technology and development	0.8		0.9		2.3		2.4
General and administrative	2.5		3.4		8.0		8.8
Total share-based compensation expense	$	4.3	$	4.7	$	12.7	$	12.4

The following table provides total share-based compensation expense by type of award:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
	(dollars in millions)
Share-based compensation expense:
Restricted stock unit expense	$	4.0	$	4.4	$	11.6	$	11.4
Performance-based restricted stock unit expense	0.2		0.1		0.7		0.1
Stock option expense	0.1		0.2		0.4		0.9
Total share-based compensation expense	$	4.3	$	4.7	$	12.7	$	12.4

Schedule of RSU Activity

A summary of RSU and PSU activity for the nine months ended September 30, 2024 is as follows:

	Nine Months Ended September 30, 2024
Restricted Stock Units and Performance-Based Restricted Stock Units	Number of Shares	Weighted-Average Grant Date Fair Value per Share		Aggregate Intrinsic Value
	(in millions, except per share amounts)
Nonvested at January 1, 2024	1.9	$	14.47	$	20.3
Granted	0.3	48.63
Vested	(0.7)	16.67		38.0
Forfeited, expired or canceled	(0.1)	17.11
Nonvested at September 30, 2024	1.4	$	19.56	$	54.7

Schedule of Option Activity

A summary of option activity for the nine months ended September 30, 2024 is as follows:

	Nine Months Ended September 30, 2024
Options	Number of Shares	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in Years)	Aggregate Intrinsic Value
	(in millions, except exercise price and term amounts)
Outstanding and exercisable at January 1, 2024	0.1	$	33.68	4.29	$	0.5
Granted	—	—
Exercised	—	7.05			123.6
Forfeited, expired or canceled	—	82.00
Outstanding and exercisable at September 30, 2024	0.1	$	33.99	3.55	$	2.9